Endo chops sales force after ditching pain drug

The Irish biopharma plans to pump the resources saved from the decision into its branded drug portfolio.

By Jacob Bell • Dec. 8, 2016

Pfizer hit with record fine in UK for drug price hike

A U.K. competition regulator fined Pfizer and Flynn Pharma about $113 million for sharply increasing the price of an epilepsy drug by as much as 2600%. 

By Ned Pagliarulo • Dec. 7, 2016

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Report: Biosimilars, specialty drugs inversely impact drug spend

While specialty drugs can be pricey and are slated to take up a bigger chunk of drug spending, biosimilars could curb the amount stakeholders pay for some drugs.

By Jacob Bell • Dec. 7, 2016

Novo Nordisk becomes latest pharma to criticize pricing system

The Danish drugmaker blames a complicated pricing system in the U.S. that hurts profits and doesn't celebrate innovation. 

By Lisa LaMotta • Dec. 7, 2016

QuintilesIMS projects slower drug spending growth through 2021

The annual report cited loss of patent exclusivity and greater rebate use as reasons for the slower growth.

By Jacob Bell • Dec. 5, 2016

Eli Lilly, Boehringer secure CV label for Jardiance

The FDA gave the companies an early Christmas present, approving an expanded indication for the diabetes drug which Lilly hopes will be a catalyst for sales. 

By Ned Pagliarulo • Dec. 2, 2016

Biofrontera expands US marketing for skin drug

The German biotech company is expanding its sales force as it commercializes its drug for actinic keratosis in the U.S.

By Judy Packer-Tursman • Nov. 30, 2016

Novo Nordisk pulls ad from Breitbart

The Danish biopharma joins Kellogg, Allstate and the San Diego Zoo, among others, in yanking ads from the website.

By Jacob Bell • Nov. 30, 2016

Valeant grows Salix sales team as deal rumors swirl

The beleaguered specialty pharma is growing the sales force for Xifaxan and Relistor, as new speculation surfaces about a potential sale of Salix.  

By Suzanne Elvidge • Nov. 30, 2016

Novartis donates $10M in generics to global relief

This donation is the latest iteration of the big pharma's long-standing collaboration with Americares.

By Judy Packer-Tursman • Nov. 23, 2016

Walgreens expands partnership providing patient drug reviews

The deal will provide more detailed product reviews from online forum PatientLikeMe's more than 400,000 users.

By Jacob Bell • Nov. 22, 2016

Novo, Sanofi get same-day approval for diabetes drug combos

The FDA's approvals put both companies on equal footing as they continue to struggle for a competitive advantage. 

By Jacob Bell • Nov. 22, 2016

Uncertainty reigns at Alexion

The spec pharma has put investors on edge after being opaque about potential problems with Soliris marketing practices. 

By Lisa LaMotta • Nov. 16, 2016

FDA issues warning to Supernus for 'misleading' marketing

The agency took aim at a recent video for Oxtellar RX, a product responsible for a quarter of the company's revenue.

By Jacob Bell • Nov. 16, 2016

Boxed warning added to label of Bayer's Essure

The FDA decided to require the warning in February, but solicited comments from the industry and other stakeholders on its approach. 

By Ned Pagliarulo • Nov. 16, 2016

Novartis builds social media community for heart failure patients

"Together in HF," a social network two years in the making, has attracted 500 members so far. 

By Judy Packer-Tursman • Nov. 16, 2016

Amid pricing criticism, Ariad builds patient outreach

The company debuted new engagement efforts to support its work in ALK+ lung cancer. But scrutiny over pricing practices might leave more of a mark. 

By Suzanne Elvidge • Nov. 16, 2016

Lilly touts Jardiance heart benefit ahead of FDA decision

Seeking a competitive edge, Eli Lilly presented new findings weeks before the FDA decides on labeling.

By Judy Packer-Tursman • Nov. 15, 2016

Costs for many Medicare drugs continue steady rise

The undiscounted cost of 11 drugs more than doubled last year, led by Valeant's treatment for high blood sugar, Glumetza. 

By Ned Pagliarulo • Nov. 15, 2016

Orexigen and Valeant bulk up Contrave deal

The two floundering companies expanded a marketing partnership into new territories. 

By Lisa LaMotta • Nov. 9, 2016

FDA invites pharma input in off-label debate

A two-day industry meeting continues Thursday, aiming to gather input on the FDA's regulatory approach to off-label drug promotion. 

By Ned Pagliarulo • Nov. 9, 2016

FDA asks how best to tweet Rx risks (in exactly twice this much space)

If a drug's benefits are promoted on social media, is posting a link to its risks enough to strike a balance?

By Judy Packer-Tursman • Nov. 9, 2016

Endo talks pricing, generics market turmoil

Generics are Endo's bread and butter, but the company acknowledged that the copycat drugs may face continued headwinds next year.

By Jacob Bell • Nov. 8, 2016

Armed with positive data, Biogen accelerates launch prep for SMA drug

Infrastructure and logistics must be adjusted to prepare for greater patient demand, the firm said at a conference

By Judy Packer-Tursman • Nov. 8, 2016

Doctors willing to prescribe biosimilars, survey shows

Yet a lack of knowledge about the FDA approval process for the copycat biologics, along with uncertainty about the drugs' safety, suggests some concerns. 

By Ned Pagliarulo • Nov. 2, 2016